The inhaled drugs contract manufacturing market was valued at USD 4.30 billion in 2026, reaching USD 8.62 billion by 2035. Growing requirement for inhaled therapies, increasing pharmaceutical outsourcing, and rising demand for specialized drug-device manufacturing capabilities are driving market growth globally.